Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry

Oral treprostinil improves pulmonary vascular compliance in pulmonary arterial hypertension

(2022) Akram Khan et al.   RESPIRATORY MEDICINE

Contemporary Risk Scores Predict Clinical Worsening in Pulmonary Arterial Hypertension - An Analysis of FREEDOM-EV

(2022) Raymond L. Benza et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

(2022) Marc Humbert et al.   EUROPEAN HEART JOURNAL

Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial

(2021) Marius M Hoeper et al.   Lancet Respiratory Medicine

Pulmonary Arterial Hypertension

(2021) Paul M. Hassoun   NEW ENGLAND JOURNAL OF MEDICINE

Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for use in Patients with Pulmonary Arterial Hypertension

(2020) Raymond L. Benza et al.   CHEST

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension: A Double-Blind, Placebo-Controlled Study

(2019) R. James White et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Novel Analysis of the Oral Treprostinil Combination Therapy Trial Data

(2016) R. James White et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Selexipag for the Treatment of Pulmonary Arterial Hypertension

(2015) Olivier Sitbon et al.   NEW ENGLAND JOURNAL OF MEDICINE

The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors

(2015) Lucie H. Clapp et al.   PROSTAGLANDINS & OTHER LIPID MEDIATORS

Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension

(2014) Marc Humbert et al.   CIRCULATION

Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension

(2013) Zhi-Cheng Jing et al.   CIRCULATION

A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor

(2013) Chabha Benyahia et al.   PROSTAGLANDINS & OTHER LIPID MEDIATORS

Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist

(2012) Brendan J. Whittle et al.   BIOCHEMICAL PHARMACOLOGY

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension

(2012) Robert C. Bourge et al.   Cardiovascular Therapeutics